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CC BY-NC-ND license (http://creativAbstract Background/Purpose: The peritoneal membrane of long-term peritoneal dialysis
(PD) patients is characterized by morphological and microvascular changes. It is said that
lactate-based peritoneal dialysate is implicated in the development of these changes. The
aim of this study is to compare the effects of long-term exposure to glucose-based, lactate-
buffered (Dianeal), and biocompatible bicarbonate/lactate-buffered, low glucose degradation
product (Physioneal) peritoneal solutions on the peritoneal membrane.
Methods: Thirty-nine incident PD patients were randomized into two groups: 19 patients with
Dianeal dialysate (Group A) and 20 with biocompatible Physioneal dialysate (Group B). All pa-
tients used automated PD for a median of 31 months in Group A and 32 months in Group B.
Three biopsies at one occasion only were taken from the peritoneal membrane at the end
of the study. All samples were collected and fixed in accordance with a standardized protocol,
and a histopathologist blinded to the clinical status and PD solutions allocated to the patients
carried out the analysis.
Results: The commonest change observed was peritoneal fibrosis, seen in 35 out of 39 cases
(89.7%); it was moderate to severe in 28 cases (71.8%) and mild in 11 (28.2%) cases. This
was followed by loss of mesothelial cells (22 cases, 56.4%), elastosis (20 cases, 51.3%),of Internal Medicine, Nephrology Division, King Fahd Hospital of the University, University of Dam-
i Arabia.
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8 A.K. Al-Hwiesh et al.increased blood vessels (15 cases, 38.5%), thick-walled blood vessels (10 cases, 25.6%), and
finally chronic inflammation and mesothelial cell hyperplasia (7 cases, 17.9%, and 6 cases,
15.4%, respectively). Of the patients with blood vessel abnormalities, 22 (88.0%) exhibited sig-
nificant fibrosis and only three (12.0%) did not. Of those without blood vessel changes, only six
(42.9%) patients exhibited similar degree of fibrosis (p < 0.01). The prevalence of vascular
changes, moderate to severe fibrosis, as well as mesothelial cell abnormalities increased as
the duration of PD increased. The prevalence of fibrosis, mesothelial cell loss, and vascular ab-
normalities increased significantly with diabetes mellitus (p < 0.001).
Conclusion: There was no difference in the effects of long-term exposure to glucose-based,
lactate-buffered, and biocompatible bicarbonate/lactate-buffered, low glucose degradation
product peritoneal solutions on the peritoneal membrane. Risk factors other than PD dialysate
composition need to be considered when assessing peritoneal membrane adequacy. The fac-
tors that were proved to be significant in our study are duration of end-stage renal disease,
diabetes mellitus, and time on PD.
背景 / 目的: 在接受長期腹膜透析 (PD) 的病人間，腹膜會出現若干的形態學與微血管變化，這些
變化被認為與採用乳酸鹽腹膜透析液有關。本研究旨在比較兩種透析液的長期暴露d乳酸鹽緩衝
之 Dianeal、與生物相容之 Physioneal 對病人腹膜的影響。
方法: 共 39位剛開始接受 PD的病人被分為兩組：19人接受 Dianeal透析液 (A組)、20人接受生
物相容之 Physioneal透析液 (B組)，所有病人接受的均為自動化 PD (APD)。研究結束時，我們對
病人腹膜進行了活組織檢驗。
結果: 在 A 組及 B 組之間，間皮細胞消失分別發生於 52.6% 及 60.0% 的病人，間皮細胞增生則分
別發生於 21.1% 及 15.0% 的病人 (p > 0.05)；嚴重間質纖維化分別發生於 42.1% 及 45.0% 的病
人，中度間質纖維化則分別發生於 31.6% 及 25.0% 的病人 (p > 0.05)。在 A 組及 B 組的病人之
間，彈性組織變性 (elastosis) 達到 “3þ” 的比率分別為 15.8% 及 20.0%，達到 “2þ” 的比率分別
為 15.8% 及 15.0% (p > 0.05)；異常微血管增加則分別出現於 42.1% 及 35.0% 的病人
(p > 0.05)。在糖尿病患者之間、及接受 PD 較久的病人之間，腹膜病理性變化的比率均有所增
加 (p < 0.001)。
結論: 長期採用以上兩種腹膜透析液於 PD病人中，並未導致不同的腹膜變化。然而，以下因素則
可能導致不同的腹膜變化：末期腎病、糖尿病、及 PD 的持續時間。Introduction
Long-term peritoneal dialysis (PD) is blamed for the pro-
gressive structural and functional alterations of the peri-
toneal membrane.1 The prominent findings in peritoneal
biopsies in PD patients are mesothelial cell abnormalities,
interstitial fibrosis, elastosis, and peritoneal membrane
vasculopathy.2 Functionally, the peritoneal membrane in
long-term PD is characterized by loss of ultrafiltration (UF)
capacity, which can generally be attributed to an increased
effective vascular surface area. Evidence is mounting that
high concentrations of glucose or lactate, glucose degra-
dation products (GDPs), and low pH of dialysate solutions
are central to the loss of peritoneal integrity. Some studies
focused on the role of GDPs in the genesis of UF failure,3e5
and others correlated the degree of peritoneal interstitial
fibrosis with interstitial and vascular GDPs.4 An inverse
relationship was found between these peritoneal histologic
changes and UF volume.5 Mateijsen et al6 described neo-
vascularization of the peritoneum of long-term PD patients,
and Aiello et al7 reported similarity between peritoneum
neovascularization in those patients and vasculopathy of
diabetic retinopathy. In an attempt to link UF failure to
different PD dialysate solutions, Seo et al8 provided evi-
dence that high glucose dialysis solutions increased the
synthesis of vascular endothelial growth factor by perito-
neal vascular endothelial cells, and pointed at therelationship between vascular endothelial growth factor,
GDPs, and neovascularization of the peritoneum. Since
then, other reports followed supporting this idea and
stressing on the alleged relationship between GDPs and
lactate concentrations in PD solutions and peritoneal
membrane pathologic changes.9e12 Recently, neutral solu-
tions with low GDPs have been developed to prevent PD-
related peritoneal damage and potentially to decrease
the incidence of UF failure; these solutions replaced
glucose with amino acids as osmolar effectors, and included
neutral pH solutions buffered with either bicarbonate/
lactate (Physioneal) or solely bicarbonate (Bicavera).13
These so-called biocompatible solutions were expected to
reduce morphological and functional deterioration of the
peritoneum in PD patients. However, their effect on peri-
toneal histology has not been fully proved so far. Moreover,
blood capillary density has been shown to increase with the
use of such solutions.14 These studies, surprisingly, did not
consider other factors that may be responsible for the
structural and functional deterioration of the peritoneal
membrane. Age, duration of end-stage renal disease
(ESRD), time on PD, as well as the effect of diabetes mel-
litus, all can play a significant role in inducing peritoneal
membrane abnormalities. Time on PD has been shown, in
longitudinal and cross-sectional studies, to negatively in-
fluence UF rates that decreased with treatment
duration.15e17 In keeping with these findings, the mean
Effect of peritoneal solutions on peritoneal membrane 9time spent on PD was significantly longer in patients with
UF failure, regardless of the type of dialysate used.18
Compared with that observed in parietal peritoneal mem-
branes from normal individuals, predialysis uremic patients
demonstrated a significantly thicker submesothelial
compact zone in addition to varying degrees of interstitial
fibrosis. The thickness was similar to that in biopsies ob-
tained from patients who had undergone hemodialysis for
varying periods before the initiation of PD. These findings
indicate that uremia itself may induce changes in the
peritoneal membranes of patients before they commence
PD.2 Contreras-Velazquez et al19 observed that uremia and
diabetes were associated with important peritoneal histo-
logical changes before starting PD treatment in a group of
65 uremic diabetic patients, compared with a group of 18
uremic nondiabetic patients and a control group of 15
nonuremic, nondiabetic patients who underwent noncom-
plicated elective abdominal surgery. They concluded that
diabetes associated with uremia was more strongly related
to peritoneal changes than uremia per se. Although it is
likely that these changes are related to the duration of
dialysis, diabetes, body mass index (BMI), and perhaps
dialysis solution components, the exact relationships are        All patients 
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Figure 1 Consort diagram demonstrating study design and
HD Z hemodialysis; PD Z peritoneal dialysis.poorly understood, as is the potential contribution of ure-
mia. The aim of the current study is to evaluate some of the
potential factors responsible for the observed peritoneal
structural and functional alterations using either lactate-
buffered or bicarbonate/lactate-buffered PD solutions.Materials and methods
Patients
This was a prospective, randomized, parallel group study,
conducted between July 2010 and March 2014 in one PD
center in Saudi Arabia evaluating incident automated PD
patients, randomized to either Dianeal (lactate buffered)
or Physioneal (bicarbonate/lactate buffered) group.
Randomization was done 1:1, and the biopsy materials were
analyzed by a histopathologist unaware of the PD treat-
ment assignment and clinical status of each patient, which
generated the treatment assignments. Seventy-five inci-
dent automated PD patients were assessed for eligibility,
and 63 patients were included in the study (Figure 1). Pa-
tients were not eligible for inclusion in the study if they hadon APD 
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or if they refused to participate (n Z 5). The change of
dialysis prescription to hypertonic glucose-based solutions
and the occurrence of peritonitis were other criteria for
exclusion from the study. Written informed consents were
obtained from all patients. The study was approved by the
UD and KFHU Ethics Committee, and was carried out ac-
cording to Helsinki’s Declaration.
The dialytic prescription consisted of 5 L of 1.36% and 5 L
of 2.27% glucose-based, lactate-buffered solutions (Dia-
neal; Baxter, Castlebar, Ireland) with 2 L of icodextrin
(Extraneal; Baxter) as the last fill in 19 patients (Group A),
and Physioneal (bicarbonate buffered) 1.36% and 2.27%
(Physioneal; Baxter) with a last fill of 2 L icodextrin in 20
patients (Group B), each fill 2.0 L. Total daily PD volume
ranged between 12L and 15 L, with a fill volume of 2.0 L/
cycle. Demographic characteristics of the patients are
shown in Table 1. All patients were subdivided according to
age (<60 years or 60 years), BMI (<30 or  30), duration
of ESRD (5 years or <5 years), diabetes mellitus (diabetic
or nondiabetic), and time on PD (<36 months
or  36 months).
All biopsy specimens (a minimum of 3 samples taken
using the same procedure for each patient) were obtained
from the parietal peritoneum under local anesthesia using
an Al-Hwiesh peritoneal biopsy needle (under patency
process), a special needle designed to obtain biopsy spec-
imens from the pleural and peritoneal membranes as well
as aspiration of pleural and peritoneal fluid. An Al-HwieshTable 1 Demographic characteristics of patients.
Group A Group B p
n Z 19 n Z 20
Age (y) 47 (38e61) 45 (41e63) NS
Female/male (%) 42.1 40.0 NS
DM, 12 (63.2) 12 (60.0) NS
Duration of
diabetes (y)
16 (10e18) 15 (9e18) NS
GFR (mL/m) 4.62 (4.39e6.37) 4.61 (4.4e6.12) NS
FBS (mmol/L) 8.1 (7.7e8.6) 7.9 (7.75e8.3) NS
Duration of
ESRD (y)
7 (5e11) 6 (6e10) NS
HTN 15 (78.9) 15 (75.0) NS
BMI 29.7 (28.7e31.4) 30.1 (27.7e30.5) NS
Time on PD (mo) 31 (21e47) 32 (20e49) NS
Kt/V
Baseline 1.95 (1.84e2.21) 2.1 (1.77e2.23) NS
At biopsy 1.88 (1.82e1.95) 1.9 (1.68e1.94) NS
PET
High 5 (26.3) 4 (20.0) NS
High average 9 (47.4) 9 (45.0) NS
Low average 5 (26.3) 6 (30.0) NS
Low 0 (0.0) 1 (0.05)
Data are presented as n (%) or median (IQR).
BMI Z body mass index; DM Z diabetes mellitus; ESRD Z end-
stage renal disease; FBS Z fasting blood sugar;
GFR Z glomerular filtration rate; HTN Z hypertension;
IQR Z interquartile range; NS Z not significant;
PET Z peritoneal equilibration test.needle is composed of a cylindrical external cannula, a
tipped point metallic introducer the length and angles of
which are easily controlled, and a metallic base cannula
that can be connected to a triway and hence to a rubber
tube through which the pleural and peritoneal fluid can
safely be obtained and drained. Pressing the metallic but-
ton is automatically followed by fast movement of a special
spring with the part designed to catch the pleural and
peritoneal bite. In addition, a plastic syringe may be
applied at the base of the plastic cannula when needed
(Figure 2). Perioperative prophylactic intravenous antibi-
otics were administered. All biopsy specimens were ob-
tained with ultrasound guidance, and patients continued PD
next day. For adequacy, each biopsy specimen was assessed
in terms of size and direction of specimen, and classified as
adequate or inadequate specimens. Adequate specimens
should contain several layers of the peritoneum (mesothe-
lial, submesothelial and adipose tissue). The direction of
embedding was almost vertical in all specimens, so the
thickness of the submesothelial layer could be measured
properly. Adequate specimens must contain postcapillary
venules with an external diameter of 25e50 mm. All inad-
equate specimens were excluded. All biopsy specimens
were separately examined by two experienced pathologists
(M.E.-S. and N.A.-O.) who were unaware of patient char-
acteristics and clinical details. Any interpretational dis-
crepancies were resolved using a double-headed
microscope. All biopsy specimens were collected at the end
of the study.Tissue preparation and histochemistry
Each specimen was placed on a small filter paper with the
mesothelial surface being the uppermost, then it was
formalin fixed, paraffin embedded, and sectioned perpen-
dicular to the peritoneal surface at a thickness of 4 mm. The
sections were then deparaffinized in xylene, hydrated in
descending grades of alcohol, and stained with hematoxylin
and eosin, elastic van Gieson (to highlight collagen and
elastic fibers), Congo red (for amyloid), andFigure 2 Peritoneal biopsy needle (Al-Hwiesh biopsy needle)
with biopsy specimen at the tip.
Effect of peritoneal solutions on peritoneal membrane 11immunohistochemically for CA125 (to highlight mesothelial
cells) and vascular endothelial growth factor and CD 105 (to
highlight vascular endothelium). Immunohistochemical
staining was performed in a Ventana Benchmark automated
immunostainer according to the manufacturer’s in-
structions (Ventana Medical Systems Inc., Strasbourg,
France) using the labeled streptavidinebiotin method with
3,30-diaminobenzidine as chromagen.
For each specimen, the following histologic alterations
were reported, compared with hernia sacs as normal
controls:
 Mesothelial cells: lostdhyperplasticdnormal.
 Interstitial tissue: fibrosis (1þe3þ)delastosis (1e3þ)d
normal. Fibrosis was defined as a submesothelial
compact zone measuring >150 mm, the highest value
recorded for normal individuals according to Williams
et al.2 The thickness was measured with a Ventana Iscan
Coreo scanner/image analyzer. The degree of fibrosis
was then graded semiquantitatively as mild, moderated,
and marked, with scores in the range of 1e3þ. Similar
grading was used for elastosis, as compared with hernia
sacs as controls. In normal parietal peritoneum, elastic
tissue is scanty, and is represented by elastic laminae of
small arteries and a network of elastic fibers situated
immediately beneath the basement membrane of the
peritoneal mesothelium (lamina elastica peritonei).20
The reproducibility of grading was evaluated by the
two pathologists, and, as already mentioned, any dis-
crepancies were resolved using a double-headed
microscope.
 Blood vessels: increaseddthick walleddnormal. Blood
vessels were considered increased when more than five
small vessels per mm length were found, compared with
hernia sacs as controls. According to Williams et al,2
thick-walled blood vessels were defined by varying de-
grees of subendothelial hyalinization affecting predom-
inantly venules and small veins but sometimes
arterioles, leading to narrowing of the vascular lumen or
even complete luminal obliteration.
 Chronic inflammation (mononuclear inflammatory cell
infiltration): presentdabsent.
 Amyloid deposits: presentdabsent.Residual renal functions, total fluid loss, and PD
efficacy
They were assessed at baseline (beginning of PD) and at
time of peritoneal biopsy. For this purpose, the patients
performed a 24-hour dialysate and urine collection, in
which both urea and creatinine concentrations were
measured. The glomerular filtration rate was calculated
using the following formula: glomerular filtration rate -
Z (renal creatinine clearance þ renal urea
clearance)  0.5. Total fluid loss was estimated as the sum
of urine volume and net UF. Efficacy of PD was assessed
using Kt/V at baseline and at the time of biopsy in both
groups. Transporter status was determined in the two
groups at the time of biopsy by a semiquantitative assess-
ment, peritoneal equilibration test, based on the ratio ofcreatinine in the dialysate to plasma after a standardized 4-
hour dwell (D/Pcr).21 Patients were categorized according
to peritoneal equilibration test (low, 0.5e0.64; low
average, <0.65; high average, 0.65e0.80, and high,
0.81).
Statistical analysis
Continuous variables are expressed as median and inter-
quartile range [25th (Q1) to 75th (Q3) percentiles], and
categorical variables are expressed as percentage.
Nonparametric Spearman rank test was used for continuous
variable correlation and ManneWhitney test for comparison
of two groups; p values were not adjusted for multiple
testing and should therefore be considered descriptive.
Logistic regression models are used to assess risk factors for
peritoneal membrane changes. The forward Wald method is
used for different variable profiles. Final models have the
best predictive capability for the risks of peritoneal
changes, using the odds ratio (OR) of the model variables
and leaving the OR adjusted for other factors included in
each profile.22,23 Statistical analysis was performed using
SPSS for Windows version 20 (IBM Inc., New York, NY, USA).
Results
Sixty-three patients were enrolled in the study that
extended from July 2010 until March 2014. During the study
period, 24 patients left due to transfer to hemodialysis
(nZ 4), kidney transplantation (nZ 3), peritonitis (nZ 5),
or prescription of hypertonic glucose-based PD solutions
(n Z 12; Figure 1). There were no significant differences
regarding age, sex, prevalence or duration of diabetes
mellitus, blood sugar levels, duration of ESRD, glomerular
filtration rate, membrane transport type, Kt/V, time on PD,
BMI, or hypertension (Table 1) at baseline or at the time of
biopsy. The median (interquartile range) daily urine volume
at baseline was 1140 mL (880e1260 mL) and 1160 mL
(840e1300 mL) (p > 0.05), and at the time of biopsy 750 mL
(710e770 mL) and 780 mL (690e790 mL) for Groups A and B,
respectively (p > 0.05), whereas the median (interquartile
range) 24-hour net UF was 780 mL (680e820 mL) and 770 mL
(680e800 mL) at baseline and 620 (610e650 mL) and 640 mL
(620e670) mL at the time of biopsy for Groups A and B,
respectively (p > 0.05). No statistical significant difference
in total fluid loss between the two groups was observed
(Figure 3). The difference, however, was significant when
compared with baseline in both groups (p < 0.01). The
overall pathological changes found in the peritoneal bi-
opsies are depicted in Figure 4. The commonest change
observed was fibrosis (89.7.4%), being moderate to severe
in 28 and mild in 11 cases. This was followed by a loss of
mesothelial cells (n Z 22), elastosis (n Z 20), increased
blood vessels (nZ 15), thick-walled blood vessels (nZ 10),
chronic inflammation in (nZ 7), and finally mesothelial cell
hyperplasia (n Z 6). Amyloid deposition could not be
demonstrated in any case. Comparison between the peri-
toneal pathological changes of both groups was not statis-
tically significant (Table 2). Mesothelial cells were lost in 10
(52.6%) and 12 (60%), hyperplastic in four (21.1%) and three
(15%), and normal in five (26.3%) and five (25%) patients in
Figure 3 Median 24-hour urine volume, peritoneal net ultrafiltration, and TFL at baseline and with the use of lactate-buffered
(Dianeal) and bicarbonate-lactate-buffered (Physioneal) PD fluids (p > 0.05). PD Z peritoneal dialysis; TFL Z total fluid loss;
UF Z ultrafiltration.
Figure 4 Prevalence pattern of pathological changes seen in peritoneal biopsies. BV Z blood vessels; MC Z mesothelial cells;
Severe fibrosis Z moderate to severe.
12 A.K. Al-Hwiesh et al.Groups A and B, respectively (p > 0.05). Interstitial fibrosis
was reported as severe (3þ) in eight (42.1%) and nine (45%),
moderate (2þ) in six (31.6%) and five (25%), and mild (1þ)
in three (15.8%) and four (20.0%) patients, while there was
no interstitial fibrosis (normal) in two (10.5%) and two
(10.0%) patients in Groups A and B, respectively (p > 0.05).
Elastosis was documented as 3þ in three (15.8%) and four
(20.0%), 2þ in three (15.8%) and three (15.0%), 1þ in five
(26.3%) and five (25.0%), but normal in eight (42.1%) and
nine (45.0%) patients in Groups A and B, respectively
(p > 0.05). Normal blood vessels were found in eight
(42.1%) and seven (35.0%) patients in the two groups(p > 0.05). Abnormal capillaries were reported as increased
in eight (42.1%) and seven (35.0%), and thick walled in four
(21.1%) and six (30.0%) patients in Groups A and B,
respectively (p > 0.05). Chronic inflammatory changes
were found in four (21.1%) and three (15.0%) patients of the
two groups (p > 0.05). Of the patients with vasculopathy,
22 (88%) exhibited significant fibrosis and only three (12%)
did not (p < 0.001), and of those without vasculopathy, six
(42.9%) exhibited a similar degree of fibrosis. The preva-
lence of vascular changes increased with the duration of PD
to 76.0% for patients who had undergone PD for more than
36 months, compared with 24.0% for patients who had
Table 2 Comparison of the peritoneal pathologic changes
between the two groups.
Group A Group B p
n Z 19 n Z 20
Fibrosis
3þ 8 (42.1) 9 (45.0) NS
2þ 6 (31.6) 5 (25.0) NS
1þ 3 (15.8) 4 (20.0) NS
Mesothelial cells
Lost 10 (52.6) 12 (60.0) NS
Hyperplastic 4 (21.1) 3 (15.0) NS
Normal 5 (26.3) 5 (25.0) NS
Elastosis
3þ 3 (15.8) 4 (20.0) NS
2þ 3 (15.8) 3 (15.0) NS
1þ 5 (26.3) 5 (25.0) NS
Normal 8 (42.1) 9 (45.0) NS
Blood vessels
Increased 8 (42.1) 7 (35.0) NS
Thick walled 4 (21.1) 6 (30.0) NS
Normal 8 (42.1) 7 (35.0) NS
Chronic inflammation 4 (21.1) 3 (15.0) NS
Amyloid deposits 0 (0) 0 (0)
Data are presented as n (%).
NS Z not significant.
0
5
10
15
20
25
30
35
<12 12–24 25–36 >36
Time on PD (mo)
N
um
be
r o
f b
lo
od
 v
es
se
ls
 /m
m
  l
en
gt
h
Figure 5 Blood vessel density according to the duration of PD
therapy. Blood vessels were counted per surface length (in
mm) of biopsy. Data are presented as box plots, with the boxes
representing the IQR. The median value is represented by the
thick line across each box. Lines extend from the box to the
highest and lowest values. IQR Z interquartile range;
PD Z peritoneal dialysis.
Effect of peritoneal solutions on peritoneal membrane 13undergone PD for less than 36 months (p < 0.01; Table 3 and
Figure 5). The prevalence of moderate to severe (2þe3þ)
fibrosis and moderate to severe elastosis increased as well
to 65.7% and 50% for patients with fibrosis and elastosis,
respectively, in those who had undergone PD for more than
36 months, compared with 14.3% and 5.0% for patients with
less than 36 months of PD therapy (p < 0.01). Among pa-
tients with mesothelial cell abnormalities, mesothelial cellsTable 3 Relation between time on PD and peritoneal
changes.
Peritoneal pathology
n (%)
Time on PD p
>36 mo <36 mo
Fibrosis, 35 (89.7)
3þ 15 (38.5) 2 (5.1) <0.01
2þ 8 (20.5) 3 (7.7) <0.01
1þ 4 (10.3) 3 (7.7) >0.05
Elastosis, 20 (51.3)
3þ 6 (15.4) 1 (2.6) <0.01
2þ 4 (10.3) 0 (0) <0.05
1þ 6 (15.4) 3 (7.7) <0.05
Mesothelial cell changes, 28 (71.8)
Lost 15 (38.5) 7 (17.9) <0.01
Hyperplastic 5 (12.8) 1 (2.6) <0.01
Blood vessels, 25 (64.1)
Increased 11 (28.2) 4 (10.3) <0.01
Thick walled 8 (20.5) 2 (5.1) <0.01
Chronic inflammation, 7 (17.9) 4 (10.3) 3 (7.7) NS
PD Z peritoneal dialysis; NS Z not significant.were lost in 53.6% patients who underwent PD for more
than 36 months compared with 25.0% patients who had
undergone PD for less than 36 months (p < 0.05; Table 3).
Twenty-one (60.0%) of the 35 biopsy samples with fibrosis,
16 (57.1%) of the 28 biopsy samples with mesothelial
changes, 12 (60.0%) of the 20 biopsy samples with elastosis,
and 18 (72.0%) of the 25 biopsy samples with vascular ab-
normalities belong to patients with diabetes mellitus
(p < 0.01; Figure 6). Logistic regression models that predict
the risk of the peritoneal membrane depending on the
variables introduced as potential risk factors of peritoneal
membrane abnormalities showed age, duration of diabetes
mellitus, BMI, duration of ESRD, type of dialysate (Dianeal
vs. Physioneal), and time on PD as risk factors. Multivariate
regression analysis showed diabetes mellitus as a significantFigure 6 Prevalence of peritoneal abnormalities in relation
to diabetes mellitus. MC Z mesothelial cell;
Vascular Z vascular abnormalities.
Table 4 Risk factors for structural changes in the peri-
toneum of PD population (obtained by logistic regression).
p OR 95% CI
Fibrosis
Age 60 y 0.73 0.95 0.78e1.16
BMI 30 0.88 0.99 0.86e1.15
Lactate-based dialysate 0.51 1.03 0.95e1.12
Duration of ESRD (5 y) <0.01 0.16 1.05e1.25
Time on PD (36 m) <0.001 1.42 1.17e1.73
Diabetes mellitus <0.01 1.16 1.02e1.31
Vasculopathy
Age 60 y 0.77 1.03 0.86e1.22
BMI 30 0.36 1.12 0.88e1.42
Lactate-based dialysate 0.09 0.90 0.80e1.02
Duration of ESRD (5 y) <0.01 1.50 1.16e1.92
Time on PD (36 m) <0.001 1.22 1.17e1.28
Diabetes mellitus <0.001 1.39 1.20e1.61
Mesothelial cell changes
Age 60 y 0.7 1.05 0.83e1.33
BMI 30 0.46 1.27 0.76e2.14
Lactate-based dialysate 0.80 1.01 0.92e1.11
Duration of ESRD (5 y) <0.01 1.44 1.09e1.88
Time on PD (36 m) <0.001 1.41 1.18e1.72
Diabetes mellitus <0.01 1.52 1.56e2.03
BMIZ body mass index; CIZ confidence interval; ESRDZ end-
stage renal disease; ORZ odds ratio; PDZ peritoneal dialysis.
14 A.K. Al-Hwiesh et al.risk factor for peritoneal fibrosis {OR 0.16 [95% confidence
interval (CI) 1.02e1.31], p < 0.01}, vasculopathy [OR 1.39
(95% CI 1.20e1.61), p < 0.001], and mesothelial cell ab-
normalities [OR 1.52 (95% CI 1.56e2.03), p < 0.01]. Dura-
tion of ESRD (5 years) was a significant risk factor for
fibrosis [OR 0.16 (95% CI 1.05e1.25), p < 0.01], vasculop-
athy [OR 1.50 (95% CI 1.16e1.92), p < 0.01], and meso-
thelial cell abnormalities [OR 1.44 (95% CI 1.09e1.88),
p < 0.01]. Time on PD (36 months) was also proved to be a
significant risk factor for peritoneal fibrosis [OR 1.42 (95% CI
1.17e1.73), p < 0.001], vasculopathy [OR 1.22 (95% CI
1.17e1.28), p < 0.001], and mesothelial cell changes [OR
1.41 (95% CI 1.18e1.72), p < 0.001]. Age, hypertension,
type of dialysate, and BMI were not significant risk factors
(Table 4). Figures 7AeF) illustrate some of the pathological
findings in the peritoneum of our study population.Discussion
We did not find any significant difference between the two
PD dialysis solutions (lactate buffered and bicarbonate/
lactate buffered) in terms of peritoneal fibrosis, mesothe-
lial cell changes, or vascular abnormalities (p > 0.05 in
each parameter) (Tables 2 and 4). Several studies have
shown that conventional PD solutions damage the meso-
thelial cell lining of the peritoneum, cause peritoneal
membrane thickening, and lead to changes in the perito-
neal blood vessels.2,21 Dextrose lactate-based solutions
have been accused of inducing structural as well as func-
tional changes of the peritoneal membrane, which may
lead to UF failure, ultimately resulting in discontinuation ofPD.24,25 Several studies4,26,27 have incriminated not only
glucose, but also lactate and GDPs in causing mesothelial
cell life acceleration and in reducing mesothelial cell
regeneration. Advanced glycation end products (AGEs) have
been shown to accumulate in the peritoneal tissue of
continuous ambulatory peritoneal dialysis (CAPD) pa-
tients.4,24 AGE formation in the peritoneum correlates with
the development of severe interstitial fibrosis and micro-
vascular sclerosis. These changes are presumed to lead to
UF failure and being attributed to lactate-based solutions
with low pH.4,28,29 Inclusion of bicarbonate in the formu-
lation of PD solutions was intended to avoid the impairment
of certain cell functions seen with only lactate-buffered
solutions.28,30 Bicarbonate solutions are said to be supe-
rior to the corresponding lactate-based fluids,31 and hence,
it seems that the critical lowering of pH, caused by a
combination of high lactate concentration and low pH of
the dialysis fluids, is responsible for the deleterious effects
on the peritoneal membrane.32 Glucose per se or in hy-
pertonic solutions along with its degradation products is
said to be responsible for the peritoneal damage; the
combination of glucose and lactate in acidic pH is probably
detrimental to mesothelial cell function and viability.29,32
This was not shown in our study, where both lactate-
buffered PD solutions with relatively high levels of GDPs
and bicarbonate/lactate-buffered PD solutions with a low
GDP concentration had similar effects on the peritoneal
structure and function. One explanation may be that the
use of hypertonic glucose PD solutions was not allowed in
this study, with patients requiring such solutions being
excluded from the study. Major complications are UF failure
and solute transport abnormality, which are associated
with morphologic deteriorations of the peritoneal mem-
brane, interstitial fibrosis, and hyalinizing
vasculopathy.6,21,33e36 These morphologic alterations of the
peritoneal membrane were categorized as “peritoneal
sclerosis.” The cause of peritoneal sclerosis has been
considered as bioincompatible effects of dialysate on the
peritoneal membrane, such as high osmolarity, lactate, low
pH, AGEs, and GDPs, through various biological mechanisms
including degenerative damage on the tissue components
and abnormal biological responses.37 The difference in
peritoneal function in terms of UF volume and total fluid
loss between the two PD solutions in our study was not
significant as compared with the baseline (p > 0.05) and
compared with each other (p > 0.05). Although a number of
studies have identified various mesothelial, vascular, and
interstitial changes in the peritoneal membrane during PD,
neither the factors responsible for these changes nor the
time during which they develop has been identified.4,6,36
The changes observed include loss or degeneration of the
mesothelium, submesothelial thickening, fibrosis or scle-
rosis, changes in the structure and number of blood vessels,
and vascular basement membrane reduplication.33e35,38e42
In one of the recently published studies,2 predialysis uremic
patients demonstrated significant pathologic changes
compared with those observed in parietal peritoneal
membranes of normal individuals. The changes were similar
to those found in biopsies obtained from patients who had
undergone hemodialysis for varying periods before the
initiation of PD. Using their standardized method, Honda
et al43 confirmed that two factors other than PD treatment
Figure 7 (A) Peritoneal biopsy showing fibrosis. Note thickened submesothelial layer (201.82 mm) and thick-walled blood vessel.
H&E 50. (B) Peritoneal biopsy showing fibrosis and perivascular (arrow) and interstitial (arrow head) elastosis. Note also thick-walled
blood vessel. EVG50. (C) Peritoneal biopsy showingfibrosis and interstitial elastosis (darkbluefibers). EVG50. (D) Peritoneal biopsy
showing increased vascularity. Note brown staining of vascular endothelium. CD 105, IHC 200. (E) Thick-walled blood vessels. Note
subendothelial hyalinization and marked narrowing of vascular lumen. (F) Peritoneal biopsy showing prominent mesothelial cells
(brown). CA125, IHC 100. EVGZ elastic van Gieson; H&EZ hematoxylin and eosin; IHCZ immunohistochemical staining.
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patients: uremia and diabetes. They could also demon-
strate the presence of peritoneal fibrosis and vasculopathy
in the peritoneum before PD induction. This evidence
clearly suggested an impact of uremia on the pathogenesis
of peritoneal sclerosis. In addition, other studies demon-
strated the presence of peritoneal fibrosis and vasculopathy
in uremic pre-PD patients, and suggested that the uremia
contributed to the pathogenesis of peritoneal sclerosis.2,38
These findings indicate that uremia itself may induce
changes in the peritoneal membranes of patients before
they commence PD, which may represent changes related
to chronic humoral inflammation.44 Moreover, the report by
Honda et al43 demonstrated clearly that the thickness of
the submesothelial zone in PD patients (492e266 mm) was
not different from that in uremic predialysis patients
(492  207 mm). In our study, we could clearly demonstrate
that the duration of ESRD, and hence the duration of the
uremic state, was a significant risk factor for thedevelopment of peritoneal fibrosis, as well as mesothelial
cell changes and peritoneal neovascularization. Multivar-
iate analysis of our PD population showed that patients who
had ESRD for 5 years had a higher risk of developing
structural changes (peritoneal fibrosis, mesothelial
changes, and vascular abnormalities) (Table 3). Moreover,
the duration of ESRD in our patient population was a sig-
nificant determinant of peritoneal vascular abnormalities
as well as mesothelial cell loss [p < 0.001, OR 1.42 (95% CI
1.49e1.69) and p < 0.001, OR 1.41 (95% CI 1.18e1.72)
respectively (Table 4)]. Di Paolo and Sacchi45, in 1989,
observed replication of the basement membrane of the
peritoneal capillaries and the mesothelium in all uremic
patients after a period of CAPD. Biopsy specimens of the
parietal peritoneum were collected from diabetic and
nondiabetic patients during insertion or repositioning of the
CAPD catheter. The basement membrane of the capillaries
and mesothelium was normal in nondiabetics on insertion of
the catheter, but after 2e66 months of CAPD, multiple
16 A.K. Al-Hwiesh et al.replications were found. In nearly all the diabetics, repli-
cation of the basement membrane of the peritoneal capil-
laries was already present before the initiation of CAPD. In
comparison of peritoneal changes between patients with
and without diabetes (Figure 6), our PD patients with dia-
betes mellitus had more severe vasculopathy and more
frequent fibrosis than PD patients without diabetes
[p < 0.001, OR 1.39 (95% CI 1.20e1.61) and p < 0.01, OR
1.27 (95% CI 1.07e1.50), respectively (Table 4)], suggesting
an additional adverse effect of long-standing diabetes on
the development of vasculopathy in uremic peritoneum.
AGEs and GDPs are possible candidates for adverse effects
on the peritoneal membrane, because both of them are
very common in uremic and diabetic peritoneum and in
various other organs.3,4,46e51 In immunohistochemistry,
AGEs were broadly stained in interstitial fibrous tissue of
uremic peritoneum and more intensely stained in PD peri-
toneum.3,4,46e49 Vessel walls of PD peritoneum were also
intensely positive for AGE staining3,4); therefore, diabetic
condition may promote AGE formation in the peritoneal
vessels and facilitate the progression of vasculopathy. The
correlation between PD duration and the severities of
peritoneal fibrosis, mesothelial cell pathology, and vascul-
opathy in our PD population supported this hypothesis
(Table 4). Whether this is attributed to the uremic state (as
time on PD may be considered as part of ESRD duration) or
to the deleterious effect of extended PD duration is still a
point of debate. Regardless of the dialysate type, our pa-
tients had satisfactory residual renal function and adequate
UF (Figure 4) at the time of biopsy. We assume (although
could not prove) that the use of icodextrin as a last fill in all
our patients might have been beneficial, as it allows sus-
tained UF during long dwells and maintains UF in the face of
increased membrane solute transport, while minimizing the
deleterious effects of local and systemic glucose expo-
sure.29 However, the current study has some drawbacks.
First, the number of patients was relatively small (39) and
the reported data may be an underestimate of the actual
real incidents that may occur in practice. Second, the study
lacked a control group. Third, although the biopsy findings
were compared with hernia sacs that served as normal
controls (baseline biopsies), it would have been better to
compare the peritoneal changes with actual baseline bi-
opsies. Fourth, the study was performed in a selected group
of PD patients, who used dialysate with a relatively low
glucose concentration (1.36% and 2.27%, lactate buffered
and bicarbonate/lactate buffered, respectively) as
described before. However, this study has the strength of
being the first to evaluate the peritoneal membrane
structural and functional changes while PD is still going on;
all previous studies evaluated the peritoneal structure
either before starting or after discontinuation of PD. In
addition, the study is the first of its kind to highlight the
significance of factors other than dialysate type on both
peritoneal function and peritoneal structure.Conclusion
Long-term PD is associated with different pathological and
functional changes. Dialysate type may not be the only
factor responsible for these changes. Risk factors, otherthan PD dialysate type, need to be taken into consideration
when assessing peritoneal membrane adequacy. The fac-
tors that were proved to be significant in our study are
duration of ESRD, diabetes mellitus, and time on PD.
Further studies on a larger number of patients are needed.Conflicts of interest
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